Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol).
NCT ID: NCT01967706
Last Updated: 2020-03-18
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
73 participants
INTERVENTIONAL
2013-08-31
2014-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol)
NCT01967719
Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)
NCT01959607
Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)
NCT01967732
Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting
NCT01970995
Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting Followed by 86 Days in an Ambulatory Setting
NCT01989156
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
mTHS then mCC
Each subject will follow the below study design:
* Day 0 = Wash-out (1 day)
* Day 1 = 1st intervention (single product use of mTHS)
* Day 2 = wash-out
* Day 3 = 2nd intervention (single product use of mCC).
mTHS
Single use of Tobacco Heating System 2.2 Menthol (mTHS)
mCC
Single use of subject's own menthol cigarette (mCC)
mCC then mTHS
Each subject will follow the below study design:
* Day 0 = Wash-out (1 day)
* Day 1 = 1st intervention (single product use of mCC)
* Day 2 = wash-out
* Day 3 = 2nd intervention (single product use of mTHS).
mTHS
Single use of Tobacco Heating System 2.2 Menthol (mTHS)
mCC
Single use of subject's own menthol cigarette (mCC)
mTHS then NRT
Each subject will follow the below study design:
* Day 0 = Wash-out (1 day)
* Day 1 = 1st intervention (single product use of mTHS)
* Day 2 = wash-out
* Day 3 = 2nd intervention (single administration of NRT)
mTHS
Single use of Tobacco Heating System 2.2 Menthol (mTHS)
NRT
Single administration of 2 mg gum (Nicorette® 2mg)
NRT then mTHS
Each subject will follow the below study design:
* Day 0 = Wash-out (1 day)
* Day 1 = 1st intervention (single administration of NRT)
* Day 2 = wash-out
* Day 3 = 2nd intervention (single product use of mTHS).
mTHS
Single use of Tobacco Heating System 2.2 Menthol (mTHS)
NRT
Single administration of 2 mg gum (Nicorette® 2mg)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
mTHS
Single use of Tobacco Heating System 2.2 Menthol (mTHS)
mCC
Single use of subject's own menthol cigarette (mCC)
NRT
Single administration of 2 mg gum (Nicorette® 2mg)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Smoking, healthy subject as judged by the Investigator.
* Subject has smoked at least 10 commercially available mCCs per day (no brand restrictions) for the last 4 weeks.
* Subject has smoked for at least the last 3 consecutive years.
* Subject does not plan to quit smoking in the next 3 months.
Exclusion Criteria
* Subject has received medication within 14 days or within 5 half-lives of a medication (whichever is longer) which has an impact on CYP2A6 activity.
* Female subject is pregnant or breast feeding.
* Female subject does not agree to use an acceptable method of effective contraception.
23 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Philip Morris Products S.A.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christelle Haziza, PhD
Role: STUDY_CHAIR
Philip Morris Products S.A.
Fumimasa Nobuoka, MD
Role: PRINCIPAL_INVESTIGATOR
Ageo Medical Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ageo Medical Clinic, 3133 Haraichi, Ageo-shi
Saitama, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZRHM-PK-05-JP
Identifier Type: OTHER
Identifier Source: secondary_id
ZRHM-PK-05-JP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.